Testosterone Treatment in a 71-Year-Old Male with Low Testosterone
Consider testosterone replacement therapy ONLY if the patient has confirmed low testosterone AND bothersome sexual dysfunction that he wants to improve; otherwise, do not initiate treatment. 1
Treatment Decision Algorithm
The 2020 American College of Physicians guideline provides clear, symptom-based guidance for this exact clinical scenario:
When TO Consider Treatment
Initiate a shared decision-making discussion about testosterone therapy if:
- The patient has documented low testosterone levels
- AND the patient has sexual dysfunction (erectile dysfunction, decreased libido)
- AND the patient specifically wants to improve sexual function 1
The discussion must cover potential benefits, harms, costs, and align with patient preferences. If you proceed with treatment, use intramuscular formulations rather than transdermal due to significantly lower costs with similar effectiveness and safety profiles 1.
When NOT to Treat
Do NOT initiate testosterone therapy for: 1
- Improving energy or vitality
- Improving physical function or muscle mass
- Improving cognition or memory
- General "anti-aging" purposes
This recommendation is explicit and based on low-certainty evidence showing insufficient benefit for these indications.
Critical Monitoring Requirements
If you initiate treatment:
- Reassess at 12 months and periodically thereafter
- Discontinue testosterone if there is no improvement in sexual function 1
- This is a trial-of-therapy approach, not lifelong commitment
Important Safety Considerations
The evidence base has important limitations. Recent data from the TRAVERSE trial (2026) showed a 43% higher fracture incidence in men receiving testosterone (HR 1.43), and no reduction in fracture risk despite improvements in bone density 2. The mechanism may involve a mismatch between rapid muscle strength gains and slower bone/tendon adaptation to increased loading.
Absolute contraindications include:
- Active breast cancer or untreated prostate cancer
- Recent myocardial infarction or stroke (within 4 months)
- Severe or decompensated heart failure 3
The Evidence Quality Reality
All recommendations are based on low-certainty evidence using GRADE methodology 1. The benefits for sexual function are modest, and robust proof of fracture prevention or cardiovascular benefit is lacking. The FDA explicitly requires labeling that testosterone products are approved only for hypogonadism due to known organic causes, not age-related decline 1.
Bottom Line for Your 71-Year-Old Patient
Ask: "Are you bothered by sexual dysfunction and do you want to improve it?"
- If YES → Consider trial of intramuscular testosterone with 12-month reassessment
- If NO or seeking treatment for fatigue/weakness/cognition → Do not treat
This is not about treating a laboratory number—it's about treating a specific symptom (sexual dysfunction) in a motivated patient who understands the uncertain benefit-risk profile.